Loading…
ACT EXEMESTANE is a brand name for Exemestane, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: ACT EXEMESTANE (exemestane tablets) is indicated for: • the sequential adjuvant treatment of postmenopausal women with estrogen receptor- positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy. Approval is based on improved disease-free survival for sequential exemestane in…
Verbatim from this product's HC label. Tap a section to expand.
1 Dosing Considerations There are no dosing considerations for ACT EXEMESTANE. 2 Recommended Dose and Dosage Adjustment The recommended dose of ACT EXEMESTANE (exemestane tablets) in early and advanced breast cancer is 25 mg once daily after a meal.
In postmenopausal women with early breast cancer, treatment with ACT EXEMESTANE should continue until completion of five years of adjuvant endocrine therapy, or until local or distant recurrence or new contralateral breast cancer. In patients with advanced breast cancer, treatment with ACT EXEMESTANE should continue until tumor progression is evident.
No dose adjustments are required for patients with hepatic or renal insufficiency. (see 10 CLINICAL PHARMACOLOGY).
Geriatric (> 65 years of age):
Healthy postmenopausal women aged 43 to 68 years were studied in the pharmacokinetic trials. Age-related alterations in exemestane pharmacokinetics were not seen over this age range.
Pediatrics (< 18 years of age):
Health Canada has not authorized an indication for pediatric use.
Dose modification for Patients with Hepatic Impairment:
Following a single 25-mg oral dose, the AUC of exemestane in patients with hepatic dysfunction (moderate hepatic impairment, Child Pugh B; severe hepatic impairment, Child Pugh C) was approximately 3 times higher than that observed in healthy volunteers.
However, no dosage adjustment is required for patients with liver impairment since exemestane was well tolerated in patients with breast cancer at doses 8 to 24 times higher than the recommended 25 mg daily dose (see 10 CLINICAL PHARMACOLOGY).
73 m2) compared with the AUC in healthy volunteers. However, no dosage adjustment is required for patients with renal impairment since exemestane was well tolerated in patients with breast cancer at doses 8 to 24 times higher than the recommended dose (see 10 CLINICAL PHARMACOLOGY).
4 Administration The recommended dose is one 25 mg tablet, once daily, by mouth. The tablet should be taken with food (preferably after a meal) at the same time each day. 5 Missed Dose If a dose of ACT EXEMESTANE is missed, then it should be taken as soon as the patient remembers unless it is almost time for the next dose, in which case the patient should not take the missed dose.
1 Adverse Reaction Overview Adjuvant Treatment of Early Breast Cancer Exemestane tolerability in postmenopausal women with early breast cancer was evaluated in two well-controlled trials: the Intergroup Exemestane Study 031 (IES) (see 14 CLINICAL TRIALS) and the 027 study (a randomized, placebo-controlled, double-blind, parallel group, phase II study specifically designed to assess the effects of exemestane on bone metabolism, hormones, lipids and coagulation factors over 2 years of treatment).
Certain adverse events, expected based on the known pharmacological properties and side effect profiles of test drugs, were actively sought through a positive checklist. Signs and symptoms were graded for severity using CTC in both studies.
Within the IES study, the presence of some illnesses/conditions was monitored through a positive checklist without assessment of severity. These included myocardial infarction, other cardiovascular disorders, gynecological disorders, osteoporosis, osteoporotic fractures, other primary cancer, and hospitalizations.
9 months for patients receiving exemestane or placebo within the 027 study. 6 months. Median duration of observation was 30 months for both groups in the 027 study. Exemestane adverse events were usually mild to moderate. 1% of patients receiving exemestane or placebo within Study 027.
Within the IES study, the most commonly reported adverse reactions were hot flushes (exemestane 22%; tamoxifen 20%), arthralgias (exemestane 18%; tamoxifen 11%), and fatigue (exemestane 16%; tamoxifen 15%). 5% of the tamoxifen-treated patients within the IES study.
There were 6 on-treatment deaths due to stroke and 3 due to cardiac failure in the exemestane-treated patients compared with 2 deaths due to stroke and 1 due to cardiac failure in the tamoxifen-treated patients. There were no deaths in Study 027.
, Musculoskeletal 09/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. 1 Pediatrics ...............................................................................................................
2 Geriatrics ............................................................................................................... 1 Dosing Considerations ...........................................................................................
2 Recommended Dose and Dosage Adjustment ....................................................... 4 Administration ....................................................................................................... 5 Missed Dose...........................................................................................................
1 Special Populations .............................................................................................. 1 Pregnant Women ............................................................................................. 2 Breast-feeding..................................................................................................
3 Pediatrics ......................................................................................................... 4 Geriatrics..........................................................................................................
11 8 ADVERSE REACTIONS ................................................................................................... 1 Adverse Reaction Overview .................................................................................
2 Clinical Trial Adverse Reactions............................................................................ 3 Less Common Clinical Trial Adverse Reactions..................................................... 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ............................................................................................................
ACT EXEMESTANE (exemestane tablets) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Exemestane in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Patients should not take 2 doses at the same time to make up for a missed dose.
Treatment of Advanced Breast Cancer after Failure on Tamoxifen:
A total of 1058 patients who had failed prior tamoxifen therapy were treated with exemestane tablets, 25 mg once daily in the clinical trials program. exemestane adverse events were usually mild to moderate. Only one death was potentially related to treatment with exemestane; an 80- year-old woman with known coronary artery disease had a myocardial infarction with multiple organ failure after 9 weeks on study treatment.
3%). 2 Clinical Trial Adverse Reactions Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.
Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use. Adjuvant Treatment of Early Breast Cancer Treatment-emergent adverse events and illnesses including all causalities and occurring with an incidence of ≥5% in either treatment group of the IES study during or within one month of the end of treatment are shown in Table 2.
8%). 7%). 1% in the tamoxifen-treated group. 8% vs. 0%), carpal tunnel […]
5 Post-Market Adverse Reactions ........................................................................... 18 9 DRUG INTERACTIONS .................................................................................................. 2 Drug Interactions Overview .................................................................................
3 Drug-Behavioural Interactions ............................................................................. 4 Drug-Drug Interactions ........................................................................................ 5 Drug-Food Interactions ........................................................................................
6 Drug-Herb Interactions ........................................................................................ 7 Drug-Laboratory Test Interactions ....................................................................... 20 10 CLINICAL PHARMACOLOGY..........................................................................................
1 Mechanism of Action ........................................................................................... 2 Pharmacodynamics .............................................................................................. 3 Pharmacokinetics .................................................................................................
21 11 STORAGE, STABILITY AND DISPOSAL ........................................................................... 23 12 SPECIAL HANDLING INSTRUCTIONS ............................................................................. 23 PART II: SCIENTIFIC INFORMATION .........................................................................................
23 13 PHARMACEUTICAL INFORMATION .............................................................................. 23 14 CLINICAL TRIALS ..........................................................................................................
1 Clinical Trials by Indication ................................................................................... 2 Comparative Bioavailability Studies ..................................................................... 40 15 MICROBIOLOGY ...........................................................................................................
40 16 NON-CLINICAL TOXICOLOGY ........................................................................................ 40 17 SUPPORTING PRODUCT MONOGRAPHS ...................................................................... 43 PATIENT MEDICATION INFORMATION […]